Zenas BioPharma Statistics
Total Valuation
ZBIO has a market cap or net worth of $688.01 million. The enterprise value is $954.20 million.
Important Dates
The next estimated earnings date is Saturday, November 16, 2024, before market open.
| Earnings Date | Nov 16, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ZBIO has 39.79 million shares outstanding. The number of shares has increased by 3.89% in one year.
| Shares Outstanding | 39.79M |
| Shares Change (YoY) | +3.89% |
| Shares Change (QoQ) | +0.85% |
| Owned by Insiders (%) | 0.63% |
| Owned by Institutions (%) | 27.66% |
| Float | 27.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.65 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 19.08 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.82, with a Debt / Equity ratio of 0.00.
| Current Ratio | 4.82 |
| Quick Ratio | 4.70 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $438,596 |
| Profits Per Employee | -$480,325 |
| Employee Count | 114 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ZBIO has paid $301,000 in taxes.
| Income Tax | 301,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | -2.35 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 318,006 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ZBIO had revenue of $50.00 million and -$54.76 million in losses. Loss per share was -$4.07.
| Revenue | 50.00M |
| Gross Profit | -36.22M |
| Operating Income | -56.44M |
| Pretax Income | -54.46M |
| Net Income | -54.76M |
| EBITDA | -56.31M |
| EBIT | -56.44M |
| Loss Per Share | -$4.07 |
Full Income StatementBalance Sheet
The company has $183.93 million in cash and $508,000 in debt, giving a net cash position of $183.42 million or $4.61 per share.
| Cash & Cash Equivalents | 183.93M |
| Total Debt | 508,000 |
| Net Cash | 183.42M |
| Net Cash Per Share | $4.61 |
| Equity (Book Value) | 160.83M |
| Book Value Per Share | -21.07 |
| Working Capital | 149.49M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$33.62 million and capital expenditures -$74,000, giving a free cash flow of -$33.69 million.
| Operating Cash Flow | -33.62M |
| Capital Expenditures | -74,000 |
| Free Cash Flow | -33.69M |
| FCF Per Share | -$0.85 |
Full Cash Flow StatementMargins
Gross margin is -72.45%, with operating and profit margins of -112.87% and -109.51%.
| Gross Margin | -72.45% |
| Operating Margin | -112.87% |
| Pretax Margin | -108.91% |
| Profit Margin | -109.51% |
| EBITDA Margin | -112.62% |
| EBIT Margin | -112.87% |
| FCF Margin | -161.33% |